Efficacy and Safety of Terazosin 4mg in patients with Benign Prostataic Hyperplasia assciated with Chronic Prostatitis/Chronic Pelvic Pain Syndrome
- Conditions
- Diseases of The genitoruinary system
- Registration Number
- KCT0004249
- Lead Sponsor
- Hallym University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Male
- Target Recruitment
- 200
? Men over 19
? Those who have had pelvic pain for at least 3 months within the last 6 months
? Those who have an The National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI) score of 15 or higher
? Those who have 8 or more International Prostate Symptom Score(IPSS) score
? A person who voluntarily decides to participate in this study and agrees in writing to the subject's consent
? Persons with hypersensitivity to hytrine-based drugs (a-blocker)
? Those who are taking cholinergic drugs and diuretics
? Those with urination disorders due to obvious causes other than enlarged prostate
? Those with urinary tract infection (midstream urine culture> 100,000 colonies / mL)
? Patients with clinically significant circulatory diseases (myocardial infarction, heart failure, angina pectoris, deep vein, pacemaker use, orthostatic hypotension, uncontrolled hypotension)
? Participants in other interventional clinical trials within 3 months of screening
? Those who have a past or present history of malignant tumors and are inappropriate for participation in research when judged by the research director or the person in charge of the research
? Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
? Other persons who are inappropriate to participate in research as judged by the research director or research manager
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of prostate symptoms improvement at week 12 relative to baseline (IPSS)
- Secondary Outcome Measures
Name Time Method Evaluation of improvement of prostatitis symptoms at week 12 compared to baseline (NIH-CPSI);Assessment of prostate symptoms improvement at week 6 relative to baseline (IPSS);Evaluation of improvement of prostatitis symptoms at week 6 compared to baseline (NIH-CPSI)